title: Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS.
abstract: Patients with HIV and AIDS are living longer because of advancements in antiretroviral therapy. These patients are often susceptible to debilitating inflammatory disorders that are refractory to standard treatment. We discuss the relationship of tumor necrosis factor-alpha and HIV and then review 27 published cases of patients with HIV being treated with tumor necrosis factor-alpha inhibitors. This review is limited because no randomized controlled trials have been performed with this patient population. Regardless, we propose that reliable seropositive patients, who are adherent to medication regimens and frequent monitoring and have failed other treatment modalities, should be considered for treatment with tumor necrosis factor-alpha inhibitors.
authors.affiliation: Department of Dermatology, State University of New York-Downstate, Brooklyn, New York. Electronic address: s.m.gallitano@gmail.com.
authors.forename: Stephanie M
authors.initials: SM
authors.lastname: Gallitano
authors.affiliation: Department of Dermatology, State University of New York-Downstate, Brooklyn, New York.
authors.forename: Laura
authors.initials: L
authors.lastname: McDermott
authors.affiliation: Division of Pediatric Allergy and Immunology, National Jewish Health, Denver, Colorado.
authors.forename: Kanwaljit
authors.initials: K
authors.lastname: Brar
authors.affiliation: Department of Dermatology, State University of New York-Downstate, Brooklyn, New York.
authors.forename: Eve
authors.initials: E
authors.lastname: Lowenstein
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D000068879:Adalimumab / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism*; D018572:Disease-Free Survival; D000068800:Etanercept / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods; D011379:Prognosis; D058996:Quality Improvement; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept
keywords: AIDS; HIV; autoimmune disease; hidradenitis suppurativa; inflammatory bowel disease; opportunistic infections; psoriasis; rheumatoid arthritis; tumor necrosis factor-alpha